Drugs / AK006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06577116 | Aug 2024 → May 2025 | chronic idiopathic urticaria | Allakos Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06072157 | Aug 2023 → May 2025 | chronic urticaria | Allakos Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072157 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06072157 ↗ |